中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
6期
91-92,93
,共3页
杨萌%王显良%李波%蔡瑞艳
楊萌%王顯良%李波%蔡瑞豔
양맹%왕현량%리파%채서염
苯磺酸左旋氨氯地平%缬沙坦%原发性高血压%临床疗效
苯磺痠左鏇氨氯地平%纈沙坦%原髮性高血壓%臨床療效
분광산좌선안록지평%힐사탄%원발성고혈압%림상료효
Levamlodipine besylate%Valsartan%Primary hypertension%Clinical efficacy
目的：评价苯磺酸左旋氨氯地平联合缬沙坦治疗原发性高血压的临床疗效及安全性。方法：选取2010年5月-2012年5月在本院门诊就诊的130例原发性高血压患者，按照随机数字表法将其分为对照组和观察组各65例，对照组给予每日口服2.5 mg苯磺酸左旋氨氯地平，观察组在对照组的基础上，每日加服80 mg缬沙坦，两组患者中若治疗1周后，患者血压未恢复不理想，可使口服苯磺酸左旋氨氯地平剂量增至5 mg，缬沙坦剂量增至160 mg，连续治疗6周。对两组患者治疗效果及不良反应进行观察比较。结果：两组患者经治疗后，收缩压及舒张压均明显低于治疗前，差异均有统计学意义（P<0.05）；且治疗组患者的收缩压及舒张压降低差值与对照组比较差异无统计学意义（P>0.05）。同时，经治疗后，观察组的总有效率96.9%明显高于对照组的84.6%，差异有统计学意义（P<0.05）。两组患者在治疗过程中无严重不良反应。结论：原发性高血压患者采用苯磺酸左旋氨氯地平联合缬沙坦进行治疗能有效地对血压情况进行改善，与单用苯磺酸左旋氨氯地平比较，治疗效果更好，值得临床推广应用。
目的：評價苯磺痠左鏇氨氯地平聯閤纈沙坦治療原髮性高血壓的臨床療效及安全性。方法：選取2010年5月-2012年5月在本院門診就診的130例原髮性高血壓患者，按照隨機數字錶法將其分為對照組和觀察組各65例，對照組給予每日口服2.5 mg苯磺痠左鏇氨氯地平，觀察組在對照組的基礎上，每日加服80 mg纈沙坦，兩組患者中若治療1週後，患者血壓未恢複不理想，可使口服苯磺痠左鏇氨氯地平劑量增至5 mg，纈沙坦劑量增至160 mg，連續治療6週。對兩組患者治療效果及不良反應進行觀察比較。結果：兩組患者經治療後，收縮壓及舒張壓均明顯低于治療前，差異均有統計學意義（P<0.05）；且治療組患者的收縮壓及舒張壓降低差值與對照組比較差異無統計學意義（P>0.05）。同時，經治療後，觀察組的總有效率96.9%明顯高于對照組的84.6%，差異有統計學意義（P<0.05）。兩組患者在治療過程中無嚴重不良反應。結論：原髮性高血壓患者採用苯磺痠左鏇氨氯地平聯閤纈沙坦進行治療能有效地對血壓情況進行改善，與單用苯磺痠左鏇氨氯地平比較，治療效果更好，值得臨床推廣應用。
목적：평개분광산좌선안록지평연합힐사탄치료원발성고혈압적림상료효급안전성。방법：선취2010년5월-2012년5월재본원문진취진적130례원발성고혈압환자，안조수궤수자표법장기분위대조조화관찰조각65례，대조조급여매일구복2.5 mg분광산좌선안록지평，관찰조재대조조적기출상，매일가복80 mg힐사탄，량조환자중약치료1주후，환자혈압미회복불이상，가사구복분광산좌선안록지평제량증지5 mg，힐사탄제량증지160 mg，련속치료6주。대량조환자치료효과급불량반응진행관찰비교。결과：량조환자경치료후，수축압급서장압균명현저우치료전，차이균유통계학의의（P<0.05）；차치료조환자적수축압급서장압강저차치여대조조비교차이무통계학의의（P>0.05）。동시，경치료후，관찰조적총유효솔96.9%명현고우대조조적84.6%，차이유통계학의의（P<0.05）。량조환자재치료과정중무엄중불량반응。결론：원발성고혈압환자채용분광산좌선안록지평연합힐사탄진행치료능유효지대혈압정황진행개선，여단용분광산좌선안록지평비교，치료효과경호，치득림상추엄응용。
Objective:To evaluate the clinical efficacy and security of Levamlodipine besylate combined with Valsartan in the treatment of primary hypertension.Method:130 patients with primary hypertension in our hospital were selected from May 2010 to May 2012,they were divided into the control group and the observation group randomly,65 cases in each group,the control group was given oral Levamlodipine besylate 2.5 mg one day,while the observation group was given oral Valsartan 80 mg one day on the basis of the control group.The Levamlodipine besylate and Valsartan dose reached to 5 mg and 160 mg respectively if the efficacy was not good after one week′s treatment.The adverse reactions and clinical efficacy of the two groups were observed and compared.Result:Systolic and diastolic pressure of patients in the two groups after treatment were lower than before treatment significantly,the differences were statistically significant(P<0.05),there were no significant difference between control and observation group after treatment(P>0.05).The total efficacy of the observation group was 96.9%,it was significantly higher than the 84.6%of control group,the difference was statistically significant(P<0.05). There were no adverse reactions in both groups.Conclusion:Levamlodipine besylate combined with Valsartan is more efficient than single Levamlodipine besylate to decrease blood pressure in the treatment of primary hypertension,is worthy of promotion.
